Dear Member, welcome to PEGS BOSTON 2018
April 30 – May 4
Location: Seaport World Trade Center, Boston MA

Nanotechnology in medicine, or nanomedicine, is a relatively new field. The use of nanoparticles to diagnose and treat diseases as well as future potential to make repairs at the cellular level has spawned great interest among the pharma and biopharma industries.

CHI’s inaugural Nanotechnology in Medicine conference seeks to bring together the interdisciplinary researchers from chemistry, engineering, biology and medicine together to explore the use of nanomaterials including nanoparticles, nanodevices, nanorobots, that will revolutionize drug delivery, diagnostics and therapeutics applications.

Link to PEGS Summit Join us!

SECURE YOUR SEAT NOW

Conference At-A-Glance

• NANOSENSING AND IMAGING KEYNOTE PRESENTATION: Development of Uniform-Sized Inorganic Nanoparticles for Clinical Applications
Taeghwan Hyeon, PhD, SNU Distinguished Professor, School of Chemical and Biological Engineering, Seoul National University

• Targeted Nanoparticles for Imaging, Drug Delivery and Biosensing
Paul Millner, PhD, Professor of Bionanotechnology, School of Biomedical Sciences, University of Leeds

• Assemble Nanoparticles in vivo for Cancer Imaging and Treatment
Jianghong Rao, PhD, Professor, Radiology and Chemistry (courtesy), Molecular Imaging Program, Cancer Biology and Biophysics Programs, Stanford University

• Biomimetic Nanotechnology Enhances Surface Detection of Circulating Tumor Cells in Peripheral Blood from Head and Neck Cancer Patients
Seungpyo Hong, PhD, Professor, Pharmaceutics, Pharmaceutical Sciences Division, School of Pharmacy, University of Wisconsin-Madison

• Digital Resolution Biomolecule Sensing by Photonic Resonator Absorption Microscopy (PRAM) with Plasmonic Nanoparticle Tags
Brian T. Cunningham, PhD, Willett Professor of Engineering, Director, Micro and Nanotech Lab, Electrical and Computer Engineering, University of Illinois at Urbana -Champaign

• NANOTHERAPEUTICS Development of Novel Antibody Directed Nanotherapeutics for the Treatment of Solid Tumors
Daryl Drummond, PhD, Head of Research, Merrimack Pharmaceuticals

• Enabling and Expanding the Use of Microbial-Derived Biologics through the Use of Tolerogenic Nanoparticles
Kei Kishimoto, PhD, CSO, Selecta Biosciences

• Safe and Effective Nanomedicines for Cancer and Inflammatory Diseases
Hayat Onyuksel, PhD, Professor, Biopharmaceutical Sciences, University of Illinois

• A Modular Platform for Targeted RNAi Therapeutics Using Biologically-Lipidated Antibodies
Itai Benhar, PhD, Professor, Molecular Microbiology and Biotechnology, The George S. Wise Faculty of Life Sciences, Tel Aviv University

• Smart, Multifunctional Liposomal Nanoformulation for Treating Fabry and Other Rare Diseases
Jose Luis Corchero Nieto, PhD, Senior Scientist, Nanobiotechnology Group, CIBER-BBN, Institute of Biotechnology and Biomedicine, Universitat Autonoma de Barcelona

• Targeted Ultrasmall Silica Nanoparticles as Next-Generation Treatment Tools for Drug Delivery
Michelle Bradbury, MD, PhD, Director, Intraoperative Imaging, Radiology, Memorial Sloan Kettering Cancer Center

• NANOCARRIERS FOR DELIVERY Nanoemulsion Technology for Intranasal Immunization Facilitates Vaccine Uptake by Antigen Presenting Cells at Mucosal Tissues, Induces Innate Immunity, and Enhances Mucosal Immunity
Ali Fattom, PhD, Senior Vice President, Vaccine R&D, NanoBio Corp.

• Designing Nanoparticles to Actively and Specifically Penetrate Solid Tumors
Jan E. Schnitzer, MD, Director, Professor of Cellular & Molecular Biology, Proteogenomics Research Institute for Systems Medicine (PRISM)

• Synthetic mRNA Nanocarriers for the in situ Programming of Disease-Specific T Cells
Matthias Stephan, MD, PhD, Associate Member, Fred Hutchinson Cancer Research Center, Associate Professor, University of Washington

• Bioresponsive Nanotechnologies for Systemic RNA Delivery to TumorsJinjun Shi, PhD, Assistant Professor, Center for Nanomedicine, Brigham and Women’s Hospital, Harvard Medical School

Pilot plant for testing of nanopharmaceuticals

Dear Member,

Spinverse is working on an EU funded project called Nanopilot, which is coordinated by Cidetec in Spain. The aim of the project is to set up a pilot plant for the cost-efficient production of polymer-based nanopharmaceuticals in small GMP batches, used e.g. for early clinical trials (download PDF HERE).

During the project, siRNA-based nanopharmaceuticals, HIV nanovaccine and hyaluronan-based spheres for drug delivery will be produced at the pilot plant. At the end of the project (around 2017-2018) the aim is to expand the pilot plant offering also to other users and other kinds of (polymeric) nanopharmaceuticals. Spinverse role in the project is to gather information and to develop the services and assess the business potential of the project, and therefore we need to reach out to potential collaborators in order to hear their needs and opinions.

More about us: Spinverse is a Finnish consultant company within open innovation. The company has been founded 2004 and today it employs 50 people. We help companies and universities to apply for public funding, to find the right partners, and to coordinate the projects.

 

 

 

 

CLINAM

European Foundation for Clinical Nanomedicine BASEL, SWITZERLAND

Join the CLINAM Summit in Basel May 8-10.

10th European and Global Conference and Exhibition for Clinical Nanomedicine & Targeted Medicine: Enabling Technologies for Personalized Medicine.

Download Info and registration in PDF, click here